RGC Stock Analysis: Buy, Sell, or Hold?
RGC - Regencell Bioscience Holdings Limited Ordinary Shares
$6.82
0.49 (7.74%)
▲
5d:
+10.53%
30d:
+8.08%
90d:
+21.57%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 30, 2026
26d
Get Alerted When RGC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: RGC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: RGC shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: RGC is currently trading at $6.82, which is considered extended relative to its 30-day fair value range of $5.57 to $6.41.
Technical Outlook: Technically, RGC is in a strong downtrend. Immediate support is located at $5.66, while resistance sits at $7.39. The stock is showing strong short-term momentum, up 7.7% recently.
Market Sentiment: RGC scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RGC is in a strong downtrend. Immediate support is located at $5.66, while resistance sits at $7.39. The stock is showing strong short-term momentum, up 7.7% recently.
Market Sentiment: RGC scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.57 -
$6.41
Company Quality Score
44/100
(HOLD)
Options IV Signal
60th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
29.5%
All Signals
- BEARISH: Price extended above range (+6.4% above its trading range)
- NEUTRAL: Options fairly priced (IV 60th percentile)
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.7%)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.57 -
$6.41
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.52
(22.2%)
Support & Resistance Levels
Support Level
$5.66
Resistance Level
$7.39
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Share & Embed Analysis
Last updated: October 03, 2026 10:21 AM ET
Data refreshes hourly during market hours. Next update: 11:21 AM
Data refreshes hourly during market hours. Next update: 11:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
